Nature Reviews Drug Discovery contents November 2014 Volume 13 Number 11 pp 781-869

If you are unable to see the message below, click here to view.

Advertisement
Download technical note:  Genome Editing: Which Should I Choose, TALEN or CRISPR? TALEN and CRISPR are great tools for gene knockout, knock-in, gene tagging, and correction of genetic defects. We compare the two technologies by analyzing Specificity Target site selection Efficiency Ease of design and construction Download now>>
TABLE OF CONTENTS
November 2014 Volume 13 Number 11		Advertisement
Impact Factor 37.231 *	In this issue Foreword Comment News and Analysis Research Highlights Reviews Correspondence Also this month Focus: US drug discovery consortia  Featured article: Drugging the undruggable RAS: Mission Possible? Adrienne D. Cox, Stephen W. Fesik, Alec C. Kimmelman, Ji Luo & Channing J. Der	What is your Protein Personality? Do you like to party like a Kinase or keep it calm and cool as a Chaperone? Find out your protein personality by taking our short quiz. Show off your results with a free* magnet to stick on your fridge or incubator! *While supplies last Take the Quiz >
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
The Smarter Choice for Your Lab, Reichert SPR Systems  Reichert SPR systems beat the competition! Unparalleled performance. Unmatched sensitivity. Robust off-the-shelf fluidics. Low operating costs. Outstanding support for your applications from expert scientists. No better value. Compare for yourself.  ReichertSPR.com/advantage
Advertisement
A picture of health Reporter Lorna Stewart travels to the German island of Lindau to meet 600 of science’s brightest young minds and 37 rock stars – Nobel laureates. In a series of four films, Stewart asks some of the most profound questions in medicine.  Watch the videos online.  Published weekly from 24th Sep- 15th Oct 2014 Supported by Mars, Incorporated
FOREWORD		Top
The driving role of consortia on the critical path to innovative therapies Janet Woodcock, Martha Brumfield, Dalvir Gill & Elias Zerhouni p781 | doi:10.1038/nrd4462 Launched a decade ago, the US Food and Drug Administration's Critical Path Initiative has helped catalyse the formation of many consortia focused on drug development challenges. Full Text | PDF
Comment: Paving the critical path of drug development: the CDER perspective Janet Woodcock p783 | doi:10.1038/nrd4435 Abstract | Full Text | PDF
Comment: The Critical Path Institute: transforming competitors into collaborators Martha Brumfield p785 | doi:10.1038/nrd4436 Abstract | Full Text | PDF | Supplementary information
Comment: Re-inventing clinical trials through TransCelerate Dalvir Gill p787 | doi:10.1038/nrd4437 Abstract | Full Text | PDF
Comment: The role of public-private partnerships in addressing the biomedical innovation challenge Maya Said & Elias Zerhouni p789 | doi:10.1038/nrd4438 Abstract | Full Text | PDF
Comment: The Biomarkers Consortium David Wholley p791 | doi:10.1038/nrd4439 Abstract | Full Text | PDF | Supplementary information
Comment: The Predictive Safety Testing Consortium and the Coalition Against Major Diseases Diane Stephenson & John-Michael Sauer p793 | doi:10.1038/nrd4440 Abstract | Full Text | PDF
Comment: The International Serious Adverse Events Consortium Arthur L. Holden, Jorge L. Contreras, Sally John & Matthew R. Nelson p795 | doi:10.1038/nrd4441 Abstract | Full Text | PDF | Supplementary information
Comment: The Clinical Trials Transformation Initiative: innovation through collaboration Pamela Tenaerts, Leanne Madre, Patrick Archdeacon & Robert M. Califf p797 | doi:10.1038/nrd4442 Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Bispecific antibodies rise again Ken Garber p799 | doi:10.1038/nrd4478 Amgen's blinatumomab is setting the stage for a bispecific revival, enabled by new formats that may solve the field's long-standing problems. PDF
Sanofi's dengue vaccine rounds final corner Asher Mullard p801 | doi:10.1038/nrd4479 An approval for a first dengue vaccine seems in sight, even if the efficacy data are not as strong as was once hoped. PDF
NEWS IN BRIEF NCI starts 'exceptional responder' hunt Asher Mullard p803 | doi:10.1038/nrd4482 PDF
Clinical trial transparency, take two Asher Mullard p803 | doi:10.1038/nrd4483 PDF
BRAIN gain Asher Mullard p803 | doi:10.1038/nrd4484 PDF
NIAID amps up vaccine adjuvant work Asher Mullard p803 | doi:10.1038/nrd4485 PDF
BIOBUSINESS BRIEFS Deal watch: Lilly buys back into the BACE race for Alzheimer's disease Megan Cully p804 | doi:10.1038/nrd4469 PDF
Patent watch: Australian court upholds Myriad's gene patent Charlotte Harrison p805 | doi:10.1038/nrd4481 PDF
AN AUDIENCE WITH Keith Blundy p806 | doi:10.1038/nrd4480 Keith Blundy, Chief Executive Officer of Cancer Research Technology, discusses new developments at the non-profit Cancer Research UK. PDF
FROM THE ANALYST'S COUCH The dyslipidaemia market Victoria Hudson p807 | doi:10.1038/nrd4475 This analysis examines new classes of drugs that are in development for dyslipidaemia — in particular PCSK9 inhibitors and CETP inhibitors — and discusses their likely impact on the dyslipidaemia market, which is currently dominated by statins. PDF
RESEARCH HIGHLIGHTS Top Muscular disorders: Satellite-boosting muscle repair p809 | doi:10.1038/nrd4471 PDF Drug Delivery: Non-invasive drug depot refill p810 | doi:10.1038/nrd4472 PDF Lung disease: IL-25 blockade could reduce virus-associated asthma attacks p810 | doi:10.1038/nrd4473 PDF Anticancer drugs: Chasing elusive targets p811 | doi:10.1038/nrd4470 PDF Antimicrobials: Commensally sourced antibiotics p812 | doi:10.1038/nrd4474 PDF IN BRIEF Anticancer drugs: Decoy receptor prevents metastasis | Cancer: Predicting synthetic lethal interactions | Drug design: Increasing stability of ADCs | Infectious disease: Durable protection against Ebola virus PDF Drug Discovery JOBS of the week Postdoctoral position in Polymer Chemistry - Drug Discovery and Development Department Fondazione Istituto Italiano di Tecnologia Postdoc Research Trainee - Drug Addition Research University of Tennessee Health Science Center Postdoctoral Fellowship-Drug Discovery Moffitt Cancer Center & Research Institute Assistant / Associate Professor of Systems Pharmacology University of Connecticut (UConn) Four-Year Science PhD Studentships Institute of Cancer Research (ICR) More Science jobs from Drug Discovery EVENT Advances & Progress in Drug Design 16.02.15 London, UK More science events from
REVIEWS		Top
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery Vladimir P. Torchilin p813 | doi:10.1038/nrd4333 Multifunctional and stimulus-sensitive nanoparticles can overcome issues associated with traditional drug delivery by, for example, improving targeting and bioavailability. Here, Torchilin highlights recent developments in these types of nanocarriers and how they can also include imaging contrast moieties to track their real-time biodistribution and accumulation at the target site. Abstract | Full Text | PDF
Drugging the undruggable RAS: Mission Possible? Adrienne D. Cox, Stephen W. Fesik, Alec C. Kimmelman, Ji Luo & Channing J. Der p828 | doi:10.1038/nrd4389 Although previous attempts to therapeutically target RAS proteins — which are frequently mutationally activated in cancer — have been unsuccessful, recent advances in our understanding of these signalling proteins have led to a renewed interest in RAS-targeted therapies. Der and colleagues discuss progress with a range of established and emerging strategies to interfere with RAS function, and highlight the most promising avenues for future anticancer drug discovery efforts. Abstract | Full Text | PDF | Supplementary information
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases Holger K. Eltzschig, Donna L. Bratton & Sean P. Colgan p852 | doi:10.1038/nrd4422 Hypoxia-inducible factors (HIFs) have important roles in ischaemic and inflammatory diseases and strategies aimed at therapeutically modulating hypoxia signalling pathways are gaining considerable attention. Here, Eltzschig and colleagues focus on a set of oxygen-sensing prolyl hydroxylases — which are responsible for marking HIFs for proteasomal degradation — and assess their emerging potential as therapeutic targets. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Dynamic bias and its implications for GPCR drug discovery Martin C. Michel, Roland Seifert & Richard A. Bond p869 | doi:10.1038/nrd3954-c3 Full Text | PDF
Advertisement
Nature Collections  RNA Sequencing Quality Control (SEQC) Articles from Nature Biotechnology, Nature Communications and Scientific Data presents results from The RNA Sequencing Quality Control (SEQC) project. This is the second phase of a collaboration between government, academic and industry researchers as part of the MicroArray Quality Control (MAQC) consortium. Produced with support from the FDA's National Center for Toxicological Research (NCTR/FDA)  and the State Key Laboratory of Genetic Engineering (SKLGE) at Fudan University
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.